In this issue of European Urology, Siva and colleagues1 report on the second prospective study of metastasis-directed therapy (MDT) for oligometastatic prostate cancer (the POPSTAR trial).
The primary endpoints were the feasibility of treating patients with single-fraction stereotactic body radiotherapy (SBRT) and tolerability. Both endpoints were met, with 97% of patients receiving the prescribed treatment and only 3% experiencing grade 3 toxicity (1 patient with a vertebral fracture). This phase 1 study confirms the results of the previously reported randomised phase 2 STOMP trial2.
1. Siva S, Bressel M, Murphy DG, et al. Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 2018;74:455–62.
2. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2018;36:446–53.
Piet Ost, M.D., Ph.D., Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium
European Urology. 2018, July 06 [Epub ahead of print], Ost, Piet, European Urology, Volume 74, Issue 4, 463 - 464